<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Actinogen Medical Ltd — News on 6ix</title>
<link>https://6ix.com/company/actinogen-medical-ltd</link>
<description>Latest news and press releases for Actinogen Medical Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 03:38:20 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/actinogen-medical-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836623278dffbe2df15c465.webp</url>
<title>Actinogen Medical Ltd</title>
<link>https://6ix.com/company/actinogen-medical-ltd</link>
</image>
<item>
<title>Correction-March2026 quarterly activity report & Appendix 4C</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/correction-march2026-quarterly-activity-report-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/correction-march2026-quarterly-activity-report-and-appendix-4c</guid>
<pubDate>Wed, 29 Apr 2026 03:38:20 GMT</pubDate>
<description>Correction-March2026 quarterly activity report & Appendix 4C</description>
</item>
<item>
<title>Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/actinogen-commences-open-label-phase-of-xanamia-alzheimers-trial-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/actinogen-commences-open-label-phase-of-xanamia-alzheimers-trial-and-provides-business-update</guid>
<pubDate>Wed, 01 Apr 2026 12:30:00 GMT</pubDate>
<description>Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial following completion of 36 weeks of treatment in the randomized phase. Highlights of the OLE: Open-label phase of up to 25 months duration, during which all participants will receive</description>
</item>
<item>
<title>ACW XanaMIA Alzheimers open label trial commences</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-xanamia-alzheimers-open-label-trial-commences</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-xanamia-alzheimers-open-label-trial-commences</guid>
<pubDate>Wed, 01 Apr 2026 02:20:05 GMT</pubDate>
<description>ACW XanaMIA Alzheimers open label trial commences</description>
</item>
<item>
<title>ACW successfully completes $16.8m Placement and SPP</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-successfully-completes-dollar168m-placement-and-spp</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-successfully-completes-dollar168m-placement-and-spp</guid>
<pubDate>Fri, 27 Feb 2026 03:54:23 GMT</pubDate>
<description>ACW successfully completes $16.8m Placement and SPP</description>
</item>
<item>
<title>ACW HY26 results - XanaMIA pivotal Alzheimers trial progress</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-hy26-results-xanamia-pivotal-alzheimers-trial-progress</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-hy26-results-xanamia-pivotal-alzheimers-trial-progress</guid>
<pubDate>Thu, 26 Feb 2026 04:48:11 GMT</pubDate>
<description>ACW HY26 results - XanaMIA pivotal Alzheimers trial progress</description>
</item>
<item>
<title>Actinogen HY2025 financial report and Appendix 4D</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/actinogen-hy2025-financial-report-and-appendix-4d</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/actinogen-hy2025-financial-report-and-appendix-4d</guid>
<pubDate>Thu, 26 Feb 2026 04:47:03 GMT</pubDate>
<description>Actinogen HY2025 financial report and Appendix 4D</description>
</item>
<item>
<title>ACW receives further $1.9m FY2025 R&D rebate from ATO</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-receives-further-dollar19m-fy2025-randd-rebate-from-ato</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-receives-further-dollar19m-fy2025-randd-rebate-from-ato</guid>
<pubDate>Wed, 11 Feb 2026 03:58:14 GMT</pubDate>
<description>ACW receives further $1.9m FY2025 R&D rebate from ATO</description>
</item>
<item>
<title>Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/actinogen-receives-positive-interim-analysis-130000388</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/actinogen-receives-positive-interim-analysis-130000388</guid>
<pubDate>Mon, 02 Feb 2026 13:00:00 GMT</pubDate>
<description>XanaMIA trial fully enrolled with final results expected in November 2026SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has recommended that the trial continue without amendment after its interim analysis. In doing so, the DMC determined that the unblinded safety and efficacy data it reviewed support continuing the trial to its expected completion in Nov</description>
</item>
<item>
<title>ACW secures funding beyond XanaMIA AD trial final results</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-secures-funding-beyond-xanamia-ad-trial-final-results</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-secures-funding-beyond-xanamia-ad-trial-final-results</guid>
<pubDate>Mon, 02 Feb 2026 04:17:06 GMT</pubDate>
<description>ACW secures funding beyond XanaMIA AD trial final results</description>
</item>
<item>
<title>ACW December 2025 quarterly activity report & Appendix 4C</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-december-2025-quarterly-activity-report-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-december-2025-quarterly-activity-report-and-appendix-4c</guid>
<pubDate>Fri, 30 Jan 2026 04:32:04 GMT</pubDate>
<description>ACW December 2025 quarterly activity report & Appendix 4C</description>
</item>
<item>
<title>Continuation of Trading Halt</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/continuation-of-trading-halt-1</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/continuation-of-trading-halt-1</guid>
<pubDate>Fri, 30 Jan 2026 04:13:21 GMT</pubDate>
<description>Continuation of Trading Halt</description>
</item>
<item>
<title>ACW positive XanaMIA Interim Analysis outcome</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-positive-xanamia-interim-analysis-outcome</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-positive-xanamia-interim-analysis-outcome</guid>
<pubDate>Fri, 30 Jan 2026 04:12:07 GMT</pubDate>
<description>ACW positive XanaMIA Interim Analysis outcome</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/trading-halt-536</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/trading-halt-536</guid>
<pubDate>Thu, 29 Jan 2026 03:24:18 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Actinogen secures $4.3m of non-dilutive R&D tax funding</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/actinogen-secures-dollar43m-of-non-dilutive-randd-tax-funding</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/actinogen-secures-dollar43m-of-non-dilutive-randd-tax-funding</guid>
<pubDate>Tue, 27 Jan 2026 03:23:17 GMT</pubDate>
<description>Actinogen secures $4.3m of non-dilutive R&D tax funding</description>
</item>
<item>
<title>Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/final-247th-participant-randomized-commences-130000304</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/final-247th-participant-randomized-commences-130000304</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>On track for interim analysis in late January 2026 and topline final results November 2026SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD) trial, the company has randomized and commenced treatment of all participants. This means that topline, final results will be available in November next year Dr Dana Hilt, CMO, commented:“There remains an enormo</description>
</item>
<item>
<title>ACW XanaMIA trial fully enrolled with 246th participant</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-xanamia-trial-fully-enrolled-with-246th-participant</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-xanamia-trial-fully-enrolled-with-246th-participant</guid>
<pubDate>Thu, 18 Dec 2025 03:07:07 GMT</pubDate>
<description>ACW XanaMIA trial fully enrolled with 246th participant</description>
</item>
<item>
<title>ACW positive XanaMIA Data Monitoring Committee meeting</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-positive-xanamia-data-monitoring-committee-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-positive-xanamia-data-monitoring-committee-meeting</guid>
<pubDate>Wed, 12 Nov 2025 05:28:02 GMT</pubDate>
<description>ACW positive XanaMIA Data Monitoring Committee meeting</description>
</item>
<item>
<title>ACW September 2025 quarterly activity report & Appendix 4C</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-september-2025-quarterly-activity-report-and-appendix-4c</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-september-2025-quarterly-activity-report-and-appendix-4c</guid>
<pubDate>Thu, 23 Oct 2025 02:41:07 GMT</pubDate>
<description>ACW September 2025 quarterly activity report & Appendix 4C</description>
</item>
<item>
<title>ACW confirms eligibility for further $1.9m RDTI</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-confirms-eligibility-for-further-dollar19m-rdti</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-confirms-eligibility-for-further-dollar19m-rdti</guid>
<pubDate>Mon, 20 Oct 2025 09:13:13 GMT</pubDate>
<description>ACW confirms eligibility for further $1.9m RDTI</description>
</item>
<item>
<title>ACW achieves early screening closure for XanaMIA trial</title>
<link>https://6ix.com/company/actinogen-medical-ltd/news/acw-achieves-early-screening-closure-for-xanamia-trial</link>
<guid isPermaLink="true">https://6ix.com/company/actinogen-medical-ltd/news/acw-achieves-early-screening-closure-for-xanamia-trial</guid>
<pubDate>Mon, 20 Oct 2025 02:25:11 GMT</pubDate>
<description>ACW achieves early screening closure for XanaMIA trial</description>
</item>
</channel>
</rss>